Medical Marijuana Inc and CannaNative LLC have entered a partnership to produce a cannabis product line and supply them to more than 560 US tribal nations.

According to the agreement, Medical Marijuana and its subsidiary HempMeds will produce Cannabidol (CBD) products for the CannaNative branded line for Native American marketplace and distribute them to tribal wellness centres, doctors, offices, pharmacies and dispensaries.

The two companies expect that the partnership will contribute to the development of hemp and cannabis-based economies.

"Advaxis Inc has announced private placement of its 2.2m common stock shares to raise gross proceeds of $30.3m."

Advaxis Inc has announced private placement of its 2.2m common stock shares to raise gross proceeds of $30.3m.

The offering is expected to be completed by 19 August and will be subscribed to by healthcare institutional specialist investors.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

See Also:

Tioma Therapeutics has raised $86m in a series A venture financing round. RiverVest Venture Partners LLC, Novo Ventures (US) Inc, F. Hoffmann-La Roche Ltd and S.R. One Limited co-led the round.

The company plans to invest the funds to advance the clinical trials of its lead drug candidate, an anti-CD47 immune checkpoint inhibitor, and also to develop its antibody portfolio.